BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/6/2025 3:09:44 AM | Browse: 79 | Download: 588
 |
Received |
|
2025-03-11 02:14 |
|
Peer-Review Started |
|
2025-03-11 02:14 |
|
First Decision by Editorial Office Director |
|
2025-04-17 01:02 |
|
Return for Revision |
|
2025-04-17 01:02 |
|
Revised |
|
2025-04-23 19:26 |
|
Publication Fee Transferred |
|
2025-04-24 03:27 |
|
Second Decision by Editor |
|
2025-05-23 02:42 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-05-23 03:32 |
|
Articles in Press |
|
2025-05-23 03:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-03 08:43 |
|
Publish the Manuscript Online |
|
2025-06-06 03:09 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhao Gao, Xiao-Yan Wang, Zhi-Gang Shen, Jia-Hua Liu, Xiao-Yun Wang, Shi-Kai Wu and Xuan Jin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National High Level Hospital Clinical Research Funding (Multi-center Clinical Research Project of Peking University First Hospital) |
No. 2022CR65 |
|
| Corresponding Author |
Shi-Kai Wu, Department of Medical Oncology, Peking University First Hospital, No. 8 Xishiku Street, Beijing 100034, China. skywu4923@sina.cn |
| Key Words |
Microsatellite stable; RAS mutation; Metastatic colorectal cancer; Immune checkpoint inhibitors; Programmed death 1 |
| Core Tip |
This manuscript addresses to evaluate the effectiveness and safety of chemotherapy combined with bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line regimen for microsatellite stable metastatic colorectal cancer. As there is currently no clinical data on the second-line treatment of advanced colorectal cancer with the combination of immunotherapy, anti-angiogenic drugs, and anti-programmed death 1 immunotherapy, we conducted a multicenter retrospective cohort clinical study to explore the safety and efficacy of this triplet therapy in second-line treatment of advanced colorectal cancer patients. |
| Publish Date |
2025-06-06 03:09 |
| Citation |
Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(21): 106939 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i21/106939.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i21.106939 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
